Recent developments in Aspergillus fumigatus research: diversity, drugs, and disease
Top Cited Papers
- 27 March 2025
- journal article
- review article
- Published by American Society for Microbiology in Microbiology and Molecular Biology Reviews
- Vol. 89 (1) , e0001123
Abstract
SUMMARY: Advances in modern medical therapies for many previously intractable human diseases have improved patient outcomes. However, successful disease treatment outcomes are often prevented due to invasive fungal infections caused by the environmental mold Aspergillus fumigatus . As contemporary antifungal therapies have not experienced the same robust advances as other medical therapies, defining mechanisms of A. fumigatus disease initiation and progression remains a critical research priority. To this end, the World Health Organization recently identified A. fumigatus as a research priority human fungal pathogen and the Centers for Disease Control has highlighted the emergence of triazole-resistant A. fumigatus isolates. The expansion in the diversity of host populations susceptible to aspergillosis and the complex and dynamic A. fumigatus genotypic and phenotypic diversity call for a reinvigorated assessment of aspergillosis pathobiological and drug-susceptibility mechanisms. Here, we summarize recent advancements in the field and discuss challenges in our understanding of A. fumigatus heterogeneity and its pathogenesis in diverse host populations.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI181215, R01AI130128)
- Cystic Fibrosis Foundation (005808G223-Cramer)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (T32AI007519)
- HHS | NIH | National Heart, Lung, and Blood Institute (T32HL134598)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI139133)
This publication has 386 references indexed in Scilit:
- Disseminated fungal infection in a patient receiving zanubrutinibClinical Case Reports, 2023
- Luciferase-Based High-Throughput Screen with Aspergillus fumigatus to Identify Antifungal Small Molecules2023
- Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplantAmerican Journal of Hematology, 2022
- Entering the era of highly effective modulator therapiesPediatric Pulmonology, 2021
- Culturing and Mating of Aspergillus fumigatusCurrent Protocols in Microbiology, 2019
- Ruxolitinib2018
- Acute progression of aspergillosis in a patient with lung cancer receiving nivolumabRespirology Case Reports, 2017
- The Extracellular Matrix of Fungal Biofilms2016
- Fungal Biofilms: Update on Resistance2016
- Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screeningHuman Mutation, 2002